DR5 agonist‐treated ovarian, TNBC, lung, and colon cancer cell lines showed significantly reduced luciferase activity (Fig 2C, Appendix Fig S4C), confirming PD‐L1‐PD‐1 interaction, a perquisite for T‐cell dysfunction and immunosuppression. Here, TNFRSF10B is linked to colonic neoplasm.